0 false false false false false false false false false false true false false false false false false No description of principal activity 2023-04-01 Sage Accounts Production Advanced 2023 - FRS102_2023 5,616 5,616 64 64 5,552 xbrli:pure xbrli:shares iso4217:GBP 12958897 2023-04-01 2024-03-31 12958897 2024-03-31 12958897 2023-03-31 12958897 2022-04-01 2023-03-31 12958897 2023-03-31 12958897 2022-03-31 12958897 core:FurnitureFittings 2023-04-01 2024-03-31 12958897 bus:OrdinaryShareClass1 2023-04-01 2024-03-31 12958897 bus:Director1 2023-04-01 2024-03-31 12958897 core:WithinOneYear 2024-03-31 12958897 core:FurnitureFittings 2024-03-31 12958897 core:ShareCapital 2024-03-31 12958897 core:ShareCapital 2023-03-31 12958897 core:RetainedEarningsAccumulatedLosses 2024-03-31 12958897 bus:SmallEntities 2023-04-01 2024-03-31 12958897 bus:AuditExemptWithAccountantsReport 2023-04-01 2024-03-31 12958897 bus:SmallCompaniesRegimeForAccounts 2023-04-01 2024-03-31 12958897 bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 12958897 bus:FullAccounts 2023-04-01 2024-03-31 12958897 bus:OrdinaryShareClass1 2024-03-31 12958897 bus:OrdinaryShareClass1 2023-03-31 12958897 core:OtherRelatedParties 2023-04-01 2024-03-31
COMPANY REGISTRATION NUMBER: 12958897
AZM Medical Enhancement Limited
Filleted Unaudited Financial Statements
31 March 2024
AZM Medical Enhancement Limited
Financial Statements
Year ended 31 March 2024
Contents
Page
Statement of financial position
1
Notes to the financial statements
2
AZM Medical Enhancement Limited
Statement of Financial Position
31 March 2024
2024
2023
Note
£
£
£
£
Fixed assets
Tangible assets
5
5,552
Current assets
Cash at bank and in hand
257
2
Creditors: amounts falling due within one year
6
12,472
--------
----
Net current (liabilities)/assets
( 12,215)
2
--------
----
Total assets less current liabilities
( 6,663)
2
-------
----
Net (liabilities)/assets
( 6,663)
2
-------
----
Capital and reserves
Called up share capital
7
2
2
Profit and loss account
( 6,665)
-------
----
Shareholders (deficit)/funds
( 6,663)
2
-------
----
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
For the year ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 25 March 2025 , and are signed on behalf of the board by:
Dr S Chetitah
Director
Company registration number: 12958897
AZM Medical Enhancement Limited
Notes to the Financial Statements
Year ended 31 March 2024
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 146 New London Road, Chelmsford, Essex, CM2 0AW, England.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Going concern
The financial statements have been prepared on a going concern basis which is dependent upon the continued support of the directors. The directors have indicated their willingness to support the company in the foreseeable future by ensuring sufficient funds are available for the company to continue trading. Therefore the directors consider the going concern basis is appropriate.
Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods supplied and services rendered, stated net of discounts and of Value Added Tax.
Income tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Tangible assets
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
Fixtures, fittings and equipment
-
20% reducing balance
Financial instruments
Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
4. Average number of employees
During the year the average number of employees was 2 (2023: 2) which consisted of the directors only.
5. Tangible assets
Fixtures, fittings and equipment
£
Cost
At 1 April 2023
Additions
5,616
-------
At 31 March 2024
5,616
-------
Depreciation
At 1 April 2023
Charge for the year
64
-------
At 31 March 2024
64
-------
Carrying amount
At 31 March 2024
5,552
-------
At 31 March 2023
-------
6. Creditors: amounts falling due within one year
2024
2023
£
£
Accruals and deferred income
836
Director loan accounts
11,636
--------
----
12,472
--------
----
7. Called up share capital
Issued, called up and fully paid
2024
2023
No.
£
No.
£
Ordinary shares of £ 1 each
2
2
2
2
----
----
----
----
8. Related party transactions
At the balance sheet date the company owed the directors £11,636 (2023: £nil) in the form of a loan account. This loan, which is shown amongst creditors, is interest free and repayable on demand.